{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:28:52Z","timestamp":1778182132277,"version":"3.51.4"},"reference-count":101,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRCI-HRB-2020-022"],"award-info":[{"award-number":["HRCI-HRB-2020-022"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001637","name":"Trinity College Dublin","doi-asserted-by":"publisher","award":["AK is a holder of a Postgraduate Ussher Felloship from Trinity College Dublin, The Unicversity of Dublin, Ireland."],"award-info":[{"award-number":["AK is a holder of a Postgraduate Ussher Felloship from Trinity College Dublin, The Unicversity of Dublin, Ireland."]}],"id":[{"id":"10.13039\/501100001637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Multiple myeloma (MM) is a hematological malignancy originated in the bone marrow and characterized by unhindered plasma cell proliferation that results in several clinical manifestations. Although the main role of blood platelets lies in hemostasis and thrombosis, platelets also play a pivotal role in a number of other pathological conditions. Platelets are the less-explored components from the tumor microenvironment in MM. Although some studies have recently revealed that MM cells have the ability to activate platelets even in the premalignant stage, this phenomenon has not been widely investigated in MM. Moreover, thrombocytopenia, along with bleeding, is commonly observed in those patients. In this review, we discuss the hemostatic disturbances observed in MM patients and the dynamic interaction between platelets and myeloma cells, along with present and future potential avenues for the use of platelets for diagnostic and therapeutic purposes.<\/jats:p>","DOI":"10.3390\/ijms242115855","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T03:29:33Z","timestamp":1698809373000},"page":"15855","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Bleeding and Thrombosis in Multiple Myeloma: Platelets as Key Players during Cell Interactions and Potential Use as Drug Delivery Systems"],"prefix":"10.3390","volume":"24","author":[{"given":"Anushka","family":"Kulkarni","sequence":"first","affiliation":[{"name":"The School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, The University of Dublin, D02 PN40 Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0934-1106","authenticated-orcid":false,"given":"Despina","family":"Bazou","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7038-5469","authenticated-orcid":false,"given":"Maria Jos\u00e9","family":"Santos-Martinez","sequence":"additional","affiliation":[{"name":"The School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, The University of Dublin, D02 PN40 Dublin, Ireland"},{"name":"School of Medicine, Trinity College Dublin, D02 R590 Dublin, Ireland"},{"name":"Trinity Biomedical Sciences Institute, Trinity College Dublin, D02 R590 Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"ref_1","unstructured":"(2022, November 05). Multiple Myeloma Source: Globocan 2020. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/35-Multiple-myeloma-fact-sheet.pdf."},{"key":"ref_2","unstructured":"(2022, November 05). Multiple myeloma|Irish Cancer Society. Available online: https:\/\/www.cancer.ie\/cancer-information-and-support\/cancer-types\/multiple-myeloma."},{"key":"ref_3","unstructured":"(2023, April 02). Key Statistics for Multiple Myeloma. Available online: https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/about\/key-statistics.html."},{"key":"ref_4","unstructured":"(2022, November 05). Incidence of Myeloma\u2014Myeloma Patients Europe. Available online: https:\/\/www.mpeurope.org\/about-myeloma\/incidence-of-myeloma\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_6","first-page":"211","article-title":"Studies on Conditions Associated with Disturbed Gamma Globulin Formation (Gammopathies)","volume":"56","author":"Waldenstrom","year":"1960","journal-title":"Harvey Lect."},{"key":"ref_7","first-page":"625199","article-title":"Game of Bones: How Myeloma Manipulates Its Microenvironment","volume":"10","author":"Joseph","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/asheducation-2005.1.340","article-title":"MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management","volume":"2005","author":"Rajkumar","year":"2005","journal-title":"Hematology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Dima, D., Jiang, D., Singh, D.J., Hasipek, M., Shah, H.S., Ullah, F., Khouri, J., Maciejewski, J.P., and Jha, B.K. (2022). Multiple Myeloma Therapy: Emerging Trends and Challenges. Cancers, 14.","DOI":"10.3390\/cancers14174082"},{"key":"ref_10","unstructured":"(2023, May 14). International Staging System for Multiple Myeloma | The IMF. Available online: https:\/\/www.myeloma.org\/international-staging-system-iss-reivised-iss-r-iss."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic Abnormalities and Survival in Multiple Myeloma: The Experience of the Intergroupe Francophone Du My\u00e9lome","volume":"109","author":"Attal","year":"2007","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Flynt, E., Bisht, K., Sridharan, V., Ortiz, M., Towfic, F., and Thakurta, A. (2020). Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma. Cells, 9.","DOI":"10.3390\/cells9020287"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and Predictive Biomarker Developments in Multiple Myeloma","volume":"14","author":"Mynott","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_14","unstructured":"(2023, September 01). Multiple Myeloma Treatment Overview | Int\u2019l Myeloma Foundation. Available online: https:\/\/www.myeloma.org\/multiple-myeloma-treatment."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood-2021-151466","article-title":"Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience","volume":"138","author":"Visram","year":"2021","journal-title":"Blood"},{"key":"ref_17","unstructured":"(2023, August 28). A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04634552."},{"key":"ref_18","unstructured":"(2023, August 30). MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04649359."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","article-title":"Mechanism and Management of Cancer-Associated Thrombosis","volume":"72","author":"Mukai","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.2008.07577.x","article-title":"Pathogenesis and Management of Bleeding and Thrombosis in Plasma Cell Dyscrasias","volume":"145","author":"Eby","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep Vein Thrombosis after Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2018-99-116300","article-title":"Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score","volume":"132","author":"Sanfilippo","year":"2018","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug\u2013Associated Thrombosis Among Patients With Multiple Myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal Metaphase Cytogenetics Predicts Venous Thromboembolism in Myeloma: Derivation and Validation of the PRISM Score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood-2021-153953","article-title":"Real World Validation of VTE Risk Models in Newly Diagnosed Multiple Myeloma in a Community Setting","volume":"138","author":"Kapur","year":"2021","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/eci.12042","article-title":"Microparticle-Associated Tissue Factor Activity in Patients with Pancreatic Cancer: Correlation with Clinicopathological Features","volume":"43","author":"Thaler","year":"2013","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MBC.0b013e32835e98a6","article-title":"Expression of Tissue Factor and Tissue Factor Pathway Inhibitor in Microparticles and Subcellular Fractions of Normal and Malignant Prostate Cell Lines","volume":"24","author":"Lwaleed","year":"2013","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1054\/bjoc.2000.1272","article-title":"Tissue Factor Expression in Breast Cancer Tissues: Its Correlation with Prognosis and Plasma Concentration","volume":"83","author":"Ueno","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/sj.bjc.6603552","article-title":"Tissue Factor Expression as a Possible Determinant of Thromboembolism in Ovarian Cancer","volume":"96","author":"Uno","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.thromres.2012.09.020","article-title":"Intratumoral Tissue Factor Expression and Risk of Venous Thromboembolism in Brain Tumor Patients","volume":"131","author":"Thaler","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1200\/JCO.2009.22.6324","article-title":"Role of Tissue Factor in Cancer","volume":"27","author":"Kasthuri","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/bjc.1980.109","article-title":"Factor X-Activating Activity from Lewis Lung Carcinoma","volume":"41","author":"Hilgard","year":"1980","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.V71.4.870.870","article-title":"A New Procoagulant in Acute Leukemia","volume":"71","author":"Falanga","year":"1988","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.leukres.2007.12.002","article-title":"Prospective Evaluation of Coagulopathy in Multiple Myeloma Patients before, during and after Various Chemotherapeutic Regimens","volume":"32","author":"Auwerda","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fotiou, D., Gavriatopoulou, M., and Terpos, E. (2020). Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. Cancers, 12.","DOI":"10.3390\/cancers12010191"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2023.01.010","article-title":"Patients with Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Have Variably Increased Thrombin Generation and Different Sensitivity to the Anticoagulant Effect of Activated Protein C","volume":"223","author":"Ghansah","year":"2023","journal-title":"Thromb. Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Nielsen, T., Kristensen, S.R., Gregersen, H., Teodorescu, E.M., Christiansen, G., and Pedersen, S. (2019). Extracellular Vesicle-Associated Procoagulant Phospholipid and Tissue Factor Activity in Multiple Myeloma. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210835"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ejh.13595","article-title":"The Incidence of Thrombocytopenia in Adult Patients Receiving Chemotherapy for Solid Tumors or Hematologic Malignancies","volume":"106","author":"Shaw","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e12001","DOI":"10.1200\/jco.2012.30.15_suppl.e12001","article-title":"Thrombocytopenia in Hematologic Malignancy and Solid Tumors in the United States","volume":"30","author":"Bennett","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_41","first-page":"e13990","article-title":"Bleeding Diathesis in Multiple Myeloma: A Rare Presentation of a Dreadful Emergency with Management Nightmare","volume":"13","author":"Rahman","year":"2021","journal-title":"Cureus"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e229312","DOI":"10.1136\/bcr-2019-229312","article-title":"Bleeding Due to Acquired Dysfibrinogenemia as the Initial Presentation of Multiple Myeloma","volume":"12","author":"Siddiq","year":"2019","journal-title":"BMJ Case Rep. CP"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1160\/TH04-03-0193","article-title":"Characterization of a Myeloma Patient with a Life-Threatening Hemorrhagic Diathesis: Presence of a Lambda Dimer Protein Inhibiting Shear-Induced Platelet Aggregation by Binding to the A1 Domain of von Willebrand Factor","volume":"93","author":"Shinagawa","year":"2005","journal-title":"Thromb. Haemost."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1089\/152581601753193869","article-title":"Bleeding Diathesis in Multiple Myeloma","volume":"10","author":"Saif","year":"2001","journal-title":"J. Hematother. Stem. Cell Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"919495","DOI":"10.3389\/fcvm.2022.919495","article-title":"Patients with Multiple Myeloma Have a Disbalanced Whole Blood Thrombin Generation Profile","volume":"9","author":"Li","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1182\/blood-2018-99-116006","article-title":"Multiple Myeloma Treatment Is Associated with Enhanced Platelet Reactivity","volume":"132","author":"Gibbins","year":"2018","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and Venous Thrombosis in Multiple Myeloma","volume":"354","author":"Knight","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1007\/s12032-012-0290-0","article-title":"Hemostatic Changes after 1 Month of Thalidomide and Dexamethasone Therapy in Patients with Multiple Myeloma","volume":"29","author":"Robak","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/ejh.12342","article-title":"Bortezomib Induces Thrombocytopenia by the Inhibition of Proplatelet Formation of Megakaryocytes","volume":"93","author":"Murai","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk Factors and Kinetics of Thrombocytopenia Associated with Bortezomib for Relapsed, Refractory Multiple Myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1182\/blood.V110.11.4820.4820","article-title":"High-Dose Dexamethasone Reduces Bortezomib-Induced Thrombocytopenia","volume":"110","author":"Quach","year":"2007","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.thromres.2007.06.013","article-title":"Effects of Bortezomib on Platelet Aggregation and ATP Release in Human Platelets, In Vitro","volume":"121","author":"Avcu","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1182\/blood.V124.21.5761.5761","article-title":"Severe Diffuse Alveolar Hemorrhage Associated with Bortezomib Administration in Patients with Multiple Myeloma","volume":"124","author":"Ayed","year":"2014","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1182\/blood-2021-152052","article-title":"Bleeding Risk in Patients with Multiple Myeloma Treated for Venous Thromboembolism","volume":"138","author":"Lutsey","year":"2021","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/09537100701767288","article-title":"Platelet-Released Supernatants Enhance Hematopoietic Stem Cell Proliferation in Vitro","volume":"19","author":"Foss","year":"2008","journal-title":"Platelets"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.V67.3.629.629","article-title":"Platelet-Leukocyte Interaction: Selective Binding of Thrombin-Stimulated Platelets to Human Monocytes, Polymorphonuclear Leukocytes, and Related Cell Lines","volume":"67","author":"Jungi","year":"1986","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1083\/jcb.118.2.445","article-title":"Identification of a Specific Glycoprotein Ligand for P-Selectin (CD62) on Myeloid Cells","volume":"118","author":"Moore","year":"1992","journal-title":"J. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"13397","DOI":"10.1038\/s41598-019-49635-7","article-title":"Platelet P-Selectin Triggers Rapid Surface Exposure of Tissue Factor in Monocytes","volume":"9","author":"Ivanov","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1158\/1078-0432.CCR-17-2003","article-title":"Platelets Enhance Multiple Myeloma Progression via Il-1b Upregulation","volume":"24","author":"Takagi","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.ejca.2013.07.010","article-title":"Inhibition of the Tumour Necrosis Factor-Alpha Autocrine Loop Enhances the Sensitivity of Multiple Myeloma Cells to Anticancer Drugs","volume":"49","author":"Tsubaki","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2005-03-1247","article-title":"Tumor Necrosis Factor-\u03b1 as Trigger of Platelet Activation in Patients with Heart Failure","volume":"106","author":"Pignatelli","year":"2005","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjh.16774","article-title":"Platelet Hyperactivation in Multiple Myeloma Is Also Evident in Patients with Premalignant Monoclonal Gammopathy of Undetermined Significance","volume":"192","author":"Gilligan","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/09537104.2013.805405","article-title":"Bone Marrow Megakaryocytes, Soluble P-Selectin and Thrombopoietic Cytokines in Multiple Myeloma Patients","volume":"25","author":"Lemancewicz","year":"2014","journal-title":"Platelets"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.thromres.2014.06.018","article-title":"Platelet Hyporeactivity in Active Myeloma","volume":"134","author":"Egan","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine Generation and Requirement of BSF-2\/IL-6 for Human Multiple Myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/cbir.2000.0497","article-title":"Role of INTERLEUKIN-6 in the Pathogenesis of Multiple Myeloma","volume":"24","author":"Hegyesi","year":"2000","journal-title":"Cell Biol. Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2003.10.005","article-title":"IL-6, RANKL, TNF-Alpha\/IL-1: Interrelations in Bone Resorption Pathophysiology","volume":"15","author":"Steeve","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","article-title":"Interleukin-6 Stimulates Thrombopoiesis through Thrombopoietin: Role in Inflammatory Thrombocytosis","volume":"98","author":"Kaser","year":"2001","journal-title":"Blood"},{"key":"ref_71","first-page":"1032","article-title":"Increased Expression of Platelet Derived Growth Factor Receptor \u03b2 on Trephine Biopsies Correlates with Advanced Myeloma","volume":"22","author":"Bilalis","year":"2017","journal-title":"J. BUON"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/hon.1014","article-title":"Role of Platelet-Derived Growth Factor-AB in Tumour Growth and Angiogenesis in Relation with Other Angiogenic Cytokines in Multiple Myeloma","volume":"30","author":"Tsirakis","year":"2012","journal-title":"Hematol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.it.2017.02.002","article-title":"PSGL-1: A New Player in the Immune Checkpoint Landscape","volume":"38","author":"Tinoco","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clml.2014.09.005","article-title":"Relationship of P-Selectin Glycoprotein Ligand-1 to Prognosis in Patients With Multiple Myeloma","volume":"15","author":"Atalay","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood-2007-04-082495","article-title":"The Syndecan-1 Heparan Sulfate Proteoglycan Is a Viable Target for Myeloma Therapy","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.1365-2141.1997.3893203.x","article-title":"Elevated Levels of Shed Syndecan-1 Correlate with Tumour Mass and Decreased Matrix Metalloproteinase-9 Activity in the Serum of Patients with Multiple Myeloma","volume":"99","author":"Dhodapkar","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Dowling, P., Hayes, C., Ting, K.R., Hameed, A., Meiller, J., Mitsiades, C., Anderson, K.C., Clynes, M., Clarke, C., and Richardson, P. (2014). Identification of Proteins Found to Be Significantly Altered When Comparing the Serum Proteome from Multiple Myeloma Patients with Varying Degrees of Bone Disease. BMC Genom., 15.","DOI":"10.1186\/1471-2164-15-904"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3324\/haematol.2012.065607","article-title":"Platelet Factor 4 Induces Cell Apoptosis by Inhibition of STAT3 via Up-Regulation of SOCS3 Expression in Multiple Myeloma","volume":"98","author":"Liang","year":"2013","journal-title":"Haematologica"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1111\/bph.14451","article-title":"The Signalling Roles of Sphingosine-1-phosphate Derived from Red Blood Cells and Platelets","volume":"175","author":"Tukijan","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbrc.2008.04.037","article-title":"Sphingosine 1-Phosphate Induces Mcl-1 Upregulation and Protects Multiple Myeloma Cells against Apoptosis","volume":"371","author":"Li","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_81","first-page":"131","article-title":"Living Cell for Drug Delivery","volume":"3","author":"Wu","year":"2022","journal-title":"Eng. Regen."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.blre.2014.10.003","article-title":"Platelet Secretion: From Haemostasis to Wound Healing and Beyond","volume":"29","author":"Golebiewska","year":"2015","journal-title":"Blood Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood.2019004119","article-title":"Platelets and Extracellular Vesicles and Their Cross Talk with Cancer","volume":"137","author":"Lazar","year":"2021","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03032368","article-title":"Potential Future Clinical Applications for the GPIIb\/IIIa Antagonist, Abciximab in Thrombosis, Vascular and Oncological Indications","volume":"6","author":"Cohen","year":"2000","journal-title":"Pathol. Oncol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1194\/jlr.R084640","article-title":"Extracellular Vesicles and Their Content in Bioactive Lipid Mediators: More than a Sack of MicroRNA","volume":"59","author":"Boilard","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1026386","DOI":"10.3389\/fphar.2022.1026386","article-title":"Platelets and Platelet Extracellular Vesicles in Drug Delivery Therapy: A Review of the Current Status and Future Prospects","volume":"13","author":"Dai","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.7150\/thno.37097","article-title":"Extracellular Vesicle-Based Drug Delivery Systems for Cancer Treatment","volume":"9","author":"Walker","year":"2019","journal-title":"Theranostics"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"McNamee, N., de la Fuente, L.R., Santos-Martinez, M.J., and O\u2019Driscoll, L. (2022). Proteomics Profiling Identifies Extracellular Vesicles\u2019 Cargo Associated with Tumour Cell Induced Platelet Aggregation. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10068-7"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s12094-021-02771-x","article-title":"Platelets for Cancer Treatment and Drug Delivery","volume":"24","author":"Xiao","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"42632","DOI":"10.1038\/srep42632","article-title":"Doxorubicin-Loaded Platelets as a Smart Drug Delivery System: An Improved Therapy for Lymphoma OPEN","volume":"7","author":"Xu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of Platelets to Tumour Metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H.N., and Gu, Z. (2017). In Situ Activation of Platelets with Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy. Nat. Biomed. Eng., 1.","DOI":"10.1038\/s41551-016-0011"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Hu, Q., Sun, W., Wang, J., Ruan, H., Zhang, X., Ye, Y., Shen, S., Wang, C., Lu, W., and Cheng, K. (2018). Conjugation of Haematopoietic Stem Cells and Platelets Decorated with Anti-PD-1 Antibodies Augments Anti-Leukaemia Efficacy. Nat. Biomed. Eng., 2.","DOI":"10.1038\/s41551-018-0310-2"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.apsb.2017.11.009","article-title":"Cell Membrane-Based Nanoparticles: A New Biomimetic Platform for Tumor Diagnosis and Treatment","volume":"8","author":"Li","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"9573","DOI":"10.1002\/adma.201603463","article-title":"Engineered Nano-Platelets for Enhanced Treatment of Multiple Myeloma and Thrombus","volume":"28","author":"Hu","year":"2016","journal-title":"Adv. Mater."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Dai, L., Liu, Y., Ding, S., Wei, X., and Chen, B. (2023). Human Nanoplatelets as Living Vehicles for Tumor-Targeted Endocytosis In Vitro and Imaging In Vivo. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041592"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10555-017-9681-1","article-title":"Platelets, Circulating Tumor Cells, and the Circulome","volume":"36","author":"Lam","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s12020-020-02523-x","article-title":"Diagnosis of Thyroid Neoplasm Using Support Vector Machine Algorithms Based on Platelet RNA-Seq","volume":"72","author":"Shen","year":"2021","journal-title":"Endocrine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"100101","DOI":"10.1016\/j.xcrm.2020.100101","article-title":"Tumor-Educated Platelet RNA for the Detection and (Pseudo)Progression Monitoring of Glioblastoma","volume":"1","author":"Sol","year":"2020","journal-title":"Cell Rep. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1002\/1878-0261.13014","article-title":"ImPlatelet Classifier: Image-Converted RNA Biomarker Profiles Enable Blood-Based Cancer Diagnostics","volume":"15","author":"Pastuszak","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_101","first-page":"689","article-title":"Tumor-Educated Platelets as a Promising Biomarker for Blood-Based Detection of Renal Cell Carcinoma","volume":"12","author":"Xiao","year":"2022","journal-title":"Front. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/21\/15855\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:15:25Z","timestamp":1760130925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/21\/15855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":101,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ijms242115855"],"URL":"https:\/\/doi.org\/10.3390\/ijms242115855","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}